Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency

Lara Rizzotto1, Mirko Pinotti, Paolo Pinton

  • 1Department of Biochemistry and Molecular Biology, University of Ferrara, Via Fossato di Mortara 74, Ferrara, Italy.

Insights

Missense mutations in factor VII (FVII) prepeptide impair endoplasmic reticulum (ER) targeting, leading to reduced protein levels and mild FVII deficiency. This study clarifies genotype-phenotype relationships in coagulation disorders.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Missense mutations can decrease protein levels via various mechanisms, including altered endoplasmic reticulum (ER) targeting.
  • The relationship between ER targeting defects and clinical phenotypes in patients with coagulation factor deficiencies is not well understood.

Purpose of the Study:

  • To investigate the impact of prepeptide mutations (L-48P, L-42P) in factor VII (FVII) on protein levels and ER targeting.
  • To correlate these molecular defects with the mild FVII deficiency observed in patients.

Main Methods:

  • Introduced mutations into native FVII and a FVII-GFP chimera to assess protein expression and ER targeting.
  • Quantified secreted and intracellular FVII levels.
  • Visualized protein localization in living cells using fluorescence microscopy.

Main Results:

  • Mutations significantly reduced both secreted and intracellular FVII levels, indicating impaired ER targeting.
  • FVII-GFP chimeras showed diffuse cytosolic localization, confirming mislocalization.
  • Residual protein levels correlated with mild FVII deficiency observed in patients.

Conclusions:

  • Prepeptide mutations L-48P and L-42P impair FVII ER targeting, causing reduced protein levels and mild FVII deficiency.
  • This study elucidates the genotype-phenotype relationship for FVII deficiency.
  • The methodology can be extended to study other coagulation serine proteases.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...